Compare GTIM & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTIM | CODX |
|---|---|---|
| Founded | 1987 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.7M | 15.6M |
| IPO Year | 1990 | 2017 |
| Metric | GTIM | CODX |
|---|---|---|
| Price | $1.14 | $0.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 75.0K | ★ 1.7M |
| Earning Date | 12-23-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 17.03 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $143,398,000.00 | $507,892.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.89 |
| P/E Ratio | $9.63 | ★ N/A |
| Revenue Growth | ★ 1.78 | N/A |
| 52 Week Low | $1.10 | $0.23 |
| 52 Week High | $2.65 | $1.55 |
| Indicator | GTIM | CODX |
|---|---|---|
| Relative Strength Index (RSI) | 33.48 | 36.70 |
| Support Level | $1.24 | $0.24 |
| Resistance Level | $1.35 | $0.30 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 10.94 | 6.35 |
Good Times Restaurants Inc is engaged in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants. It operates through two segments: Good Times Burgers and Frozen Custard restaurants which operate in the quick-service drive-through dining industry; and Bad Daddy's Burger Bar restaurants which operate in the full-service upscale casual dining industry. The company generates maximum revenue from the Bad Daddy's Burger Bar restaurants segment. Its menu categories include burgers; chicken; frozen custard; slides and drinks.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.